Artificial IntelligenceNewswireStartupsTechnology

Eight Sleep Hits $1.5B Valuation with $50M Funding Round

▼ Summary

– Eight Sleep raised $50 million in a strategic funding round led by Tether Investments, achieving a $1.5 billion valuation.
– The company sells smart mattress accessories for sleep tracking and temperature adjustment and has raised over $310 million to date.
– Funding will be used for new products, global expansion, and clinical validation, including seeking FDA approval for sleep apnea detection.
– The company is developing a sleep-focused AI agent to proactively control product features and provide personalized habit guidance.
– Eight Sleep faced a controversy when a server outage caused products to overheat, leading to the addition of an “outage mode.”

The sleep technology company Eight Sleep has secured a significant $50 million in a strategic funding round, propelling its valuation to an impressive $1.5 billion. This latest investment, spearheaded by Tether Investments, follows a substantial $100 million round closed just last August from prominent backers including HSG, Valor Equity Partners, Founders Fund, and Y Combinator. The company, known for its smart mattress accessories that monitor sleep and adjust temperature, has now raised over $310 million in total funding to date.

While the valuation from the previous round was not disclosed, the company was valued at $500 million following an $86 million Series C round in 2021. Eight Sleep reported it achieved free-cash-flow positivity in 2025 and intends to deploy the new capital toward developing new products, expanding its global footprint, and pursuing clinical validation for its technologies. Its products are currently available in more than 34 countries.

Looking beyond consumer hardware, Eight Sleep is ambitiously targeting the healthcare sector. The company has actively sought approval from the U.S. Food and Drug Administration for products designed to detect and help mitigate sleep apnea. This move signals a strategic shift from purely consumer wellness into regulated medical technology.

CEO and co-founder Matteo Franceschetti outlined a vision to build “the defining health technology company of this generation.” He described the company’s mission as creating an intelligent system that learns from the user’s body each night and proactively acts on that data to improve sleep health.

A core part of this vision involves a sophisticated, sleep-focused AI agent. This system would autonomously control the temperature, elevation, and firmness of Eight Sleep’s products to prevent sleep disruptions before they happen. The company claims this agent simulates numerous scenarios before a user goes to bed, preparing the sleep environment for optimal rest. These AI models are trained on proprietary data, and early pilot programs suggest the personalized guidance can lead users to adjust daily habits like exercise timing, caffeine consumption, and sleep schedules.

On the product front, Eight Sleep recently launched a hydro blanket for temperature regulation and a new pillow cover designed to control temperature specifically for the head and neck. However, the company faced operational challenges last October when a widespread AWS outage rendered its smart accessories inoperable. This incident caused some beds to overheat, leading Eight Sleep to implement a new “outage mode” in its products to maintain basic functionality during server connectivity issues.

The company operates in a competitive landscape, vying with brands like BedJet and ChiliPad in the smart temperature control mattress market, while also competing with Oura and Whoop in the broader wearable sleep tracking space. This latest funding round provides substantial resources for Eight Sleep to advance its integrated hardware and AI platform, aiming to solidify its position at the intersection of sleep technology and proactive health management.

(Source: TechCrunch)

Topics

funding round 95% smart mattress accessories 90% company valuation 85% sleep tracking 80% investor backing 75% temperature control 75% product development 70% ai agent 70% fda approval 65% proprietary data 65%